Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · MACROGENICS INC (MGNX)

MacroGenics reports interim 27% response rate for MGC026 in head and neck cancer

Positive Impact 3 of 5 product/contract Written later

MacroGenics presented interim Phase 1 data for MGC026, an investigational B7-H3-directed antibody-drug conjugate, at the ESMO 2026 Congress on October 23, 2026. In 22 response-evaluable head and neck cancer patients, the best overall response rate was 27% (6/22), and the company plans a front-line study combining MGC026 with pembrolizumab in early 2027. The data are preliminary, and the filing discloses no revenue, earnings or financing figures.

Key points

  • Best overall response rate of 27% (6/22) in the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort, including four confirmed and two unconfirmed partial responses
  • Grade 3 or higher treatment-related adverse events occurred in 51% of the 85-patient overall safety population, and 5% discontinued treatment
  • Plans to start a front-line SCCHN expansion cohort with pembrolizumab in early 2027; updated Stage 2 data expected in mid-2027

The filing

CompanyMACROGENICS INC (MGNX)
Form8-K, current report
Filed with the SECOct 23, 2026, 4:05 PM ET
Accession number0001125345-26-000066

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.